Fulcrum Therapeutics Is A Clinical Stage Biopharmaceutical Company Based In Cambridgemassachusettsthe Company Is Focused On Developing Small Molecule Therapies For Genetically Defined Rare Diseasesparticularly Those With Significant Unmet Medical Needstheir Goal Is To Address The Root Causes Of Gene Mis Expression Through Innovative Drug Development The Company Employs A Patient Centered Approachutilizing Proprietary Technology To Identify Drug Targetsthis Includes Using Patient Derived Cellslong Term Cell Culturingand Robust Assaysfulcrum Therapeutics Also Leverages A Diverse Small Molecule Compound Library And Customized Crispr Cas9 Guide Libraries For Precise Gene Editingtheir Pipeline Features Therapies Such As Losmapimod For Facioscapulohumeral Muscular Dystrophy And Ftx 6058 For Sickle Cell Diseasetargeting Various Therapeutic Areas Including Neuromuscular And Hematologic Disorders Led By Ceo Alex Csapirfulcrum Therapeutics Is Committed To Improving The Lives Of Patients With Rare Genetic Diseases
